Cargando…

Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial

Background: Olfactory training is the only evidence-based treatment for post-viral olfactory dysfunction. Smell disorders after SARS-CoV-2 infection have been attributed to neuroinflammatory events within the olfactory bulb and the central nervous system. Therefore, targeting neuroinflammation is on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Stadio, Arianna, D’Ascanio, Luca, Vaira, Luigi Angelo, Cantone, Elena, De Luca, Pietro, Cingolani, Cristina, Motta, Gaetano, De Riu, Giacomo, Vitelli, Federica, Spriano, Giuseppe, De Vincentiis, Marco, Camaioni, Angelo, La Mantia, Ignazio, Ferreli, Fabio, Brenner, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886808/ https://www.ncbi.nlm.nih.gov/pubmed/35450527 http://dx.doi.org/10.2174/1570159X20666220420113513

Ejemplares similares

Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial
por: Di Stadio, Arianna, et al.
Publicado: (2023)

Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial
por: Di Stadio, Arianna, et al.
Publicado: (2023)

Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study
por: Di Stadio, Arianna, et al.
Publicado: (2022)

Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells
por: Barbierato, Massimo, et al.
Publicado: (2015)

Entorhinal Cortex and Persistent Olfactory Loss in COVID-19 Patients: A Neuroanatomical Hypothesis. Comment on Fiorentino et al. Correlations between Persistent Olfactory and Semantic Memory Disorders after SARS-CoV-2 Infection. Brain Sci. 2022, 12, 714
por: De Luca, Pietro, et al.
Publicado: (2022)

Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man
por: Caltagirone, Carlo, et al.
Publicado: (2015)

Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study
por: De Luca, Pietro, et al.
Publicado: (2022)

Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
por: Facchinetti, Roberta, et al.
Publicado: (2020)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury
por: Crupi, Rosalia, et al.
Publicado: (2016)

Single-Center-Single-Blinded Clinical Trial to Evaluate the Efficacy of a Nutraceutical Containing Boswellia Serrata, Bromelain, Zinc, Magnesium, Honey, Tyndallized Lactobacillus Acidophilus and Casei to Fight Upper Respiratory Tract Infection and Otitis Media
por: Della Volpe, Antonio, et al.
Publicado: (2022)

A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury
por: Paterniti, Irene, et al.
Publicado: (2013)

Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome
por: Versace, Viviana, et al.
Publicado: (2023)

Erratum to: A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury
por: Paterniti, Irene, et al.
Publicado: (2016)

Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated With Tyro3 Receptor Upregulation
por: Facci, Laura, et al.
Publicado: (2021)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer’s Disease
por: Facchinetti, Roberta, et al.
Publicado: (2022)

Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome
por: Chirchiglia, Domenico, et al.
Publicado: (2019)

Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation
por: Roncati, Luca, et al.
Publicado: (2021)

Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?
por: Di Stadio, Arianna, et al.
Publicado: (2023)

A Supplement with Ribes Nigrum, Boswellia Serrata, Bromelain and Vitamin D to Stop Local Inflammation in Chronic Sinusitis: A Case-Control Study
por: De Luca, Pietro, et al.
Publicado: (2023)

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain
por: Cocito, Dario, et al.
Publicado: (2014)

The importance of olfactory and gustatory disorders as early symptoms of coronavirus disease (COVID-19)
por: Vaira, Luigi Angelo, et al.
Publicado: (2020)

Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies
por: Capra, Anna Paola, et al.
Publicado: (2023)

Comment on “Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain”
por: Kriek, R.
Publicado: (2014)

Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation
por: D’Amico, Ramona, et al.
Publicado: (2021)

A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis
por: Contarini, Gabriella, et al.
Publicado: (2019)

Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect
por: Petrosino, Stefania, et al.
Publicado: (2018)

Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
por: Impellizzeri, Daniela, et al.
Publicado: (2014)

The Trajectories of Olfactory Dysfunction from the First to the Omicron Wave: Are We Getting over it?
por: Vaira, Luigi Angelo, et al.
Publicado: (2022)

Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic
por: Saussez, Sven, et al.
Publicado: (2023)

Erratum to: Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
por: Impellizzeri, Daniela, et al.
Publicado: (2016)

Combination of Rehabilitative Therapy with Ultramicronized Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study
por: Scaturro, Dalila, et al.
Publicado: (2019)

The role of nasal immunoglobulins in the recovery of olfactory function in COVID-19 patients
por: Vaira, Luigi Angelo, et al.
Publicado: (2022)

In reply to: IL-6 serum level and olfactory dysfunction severity in COVID-19: correspondence
por: Vaira, Luigi Angelo, et al.
Publicado: (2022)

COVID-19 related persistent olfactory disorders represent an unprecedented challenge
por: Vaira, Luigi Angelo, et al.
Publicado: (2023)

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients
por: Noce, Annalisa, et al.
Publicado: (2021)

Long-standing gustatory and olfactory dysfunction in COVID-19 patients: a prospective study
por: Ferreli, Fabio, et al.
Publicado: (2022)

Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
por: Stochino Loi, Emanuela, et al.
Publicado: (2019)

Specific Therapy of Olfactory Disorders in COVID-19 Patients is Essential for the Prevention of Long-term Dysfunction
por: Vaira, Luigi Angelo, et al.
Publicado: (2021)

Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study
por: Albanese, Maria, et al.
Publicado: (2022)

The Beneficial Effects of Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain and Associated Mood Disorders Induced by Paclitaxel in Mice
por: Cristiano, Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tn2or84q3l1qahsoiued3jdecm